RNA-based Assays and Gene Expression Profiling for Studying RPL34 in Neurodegenerative Diseases

Target Name: RPL34-DT

NCBI ID: G285456

RPL34-DT

Other Name(s): RPL34 divergent transcript | RPL34-AS1 | RPL34 antisense RNA 1 (head to head)

RNA-based Assays and Gene Expression Profiling for Studying RPL34 in Neurodegenerative Diseases

RPL34-DT (RPL34 gene differentially expressed transcript) is a gene that has been identified as a potential drug target or biomarker in the field of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells, leading to a range of symptoms such as memory loss, cognitive decline, and difficulty with daily activities.

The RPL34 gene is a member of the RNA polymerase II (RPNI) gene family, which is involved in the production of ribosomal RNA (rRNA) in the cell. The RPNI gene family is known for the involvement in various cellular processes, including cell growth, transcription, and translation.

Expression of the RPL34 gene has been shown to be altered in the brains of individuals with Alzheimer's disease and Parkinson's disease. Studies have shown that the expression of RPL34 is reduced in the brains of individuals with these conditions, and that the levels of RPL34-DT have been associated with the severity of the disease.

Despite the promising findings, more research is needed to fully understand the role of RPL34 in the development and progression of Alzheimer's disease and Parkinson's disease. One potential approach to studying the role of RPL34 is through the use of RNA-based assays, such as RNA interference (RNAi) and gene expression profiling. These techniques can be used to reduce the expression of RPL34 and to identify potential drug targets or biomarkers for these conditions.

Another approach to studying RPL34 is through the use of animal models of the disease. Studies have shown that RPL34 is involved in the development of neurodegeneration in various animal models of Alzheimer's disease, including mouse models of the disease.

In addition to the use of RNA-based assays and animal models, researchers have also used transcriptomics techniques to study the expression of RPL34 in the brain. These techniques have allowed researchers to identify differentially expressed genes in the brain, as well as potential biomarkers for the disease.

Conclusion

The RPL34 gene has been identified as a potential drug target or biomarker in the field of neurodegenerative diseases. The expression of RPL34 is altered in the brains of individuals with Alzheimer's disease and Parkinson's disease, and studies have shown that RPL34 is involved in the development and progression of these conditions.

While more research is needed to fully understand the role of RPL34 in these diseases, the use of RNA-based assays and gene expression profiling techniques, as well as the use of animal models, has shown promising results in the study of RPL34 and its potential as a drug target or biomarker.

Overall, the RPL34 gene is a promising target for the development of new treatments for neurodegenerative diseases. Further research is needed to fully understand its role and to identify potential drug targets or biomarkers for these conditions.

Protein Name: RPL34 Divergent Transcript

The "RPL34-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL34-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets